Each month, the technology company IBM releases a podcast called “Wild Ducks,” focusing on world-changing people and ideas. For the month of July, IBM came to UNC Lineberger Comprehensive Cancer Center to learn about personalized medicine and meet their newest Wild Duck – Ned Sharpless, MD, UNC Lineberger Director and Wellcome Distinguished Professor in Cancer Research at the UNC School of Medicine.
The UCRF, a $42 million, state-appropriated fund established in 2007, continues to have a significant impact on cancer research in North Carolina.
Personalized medicine holds great promise for delivering targeted treatments to patients based on their unique genetic characteristics. Through a $3.5 million, five-year grant from the National Cancer Institute (NCI), UNC Lineberger Comprehensive Cancer Center will provide high-throughput RNA and DNA sequencing and regulatory assistance to partner institutions in the NCI’s new National Clinical Trials Network (NCTN).